Back to Search Start Over

Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.

Authors :
Bradley, John S
Bulitta, Jürgen B
Cook, Rachel
Yu, Patricia A
Iwamoto, Chelsea
Hesse, Elisabeth M
Chaney, Danielle
Yu, Yon
Kennedy, Jordan L
Sue, David
Karchmer, Adolf W
Bower, William A
Hendricks, Katherine
Source :
Clinical Infectious Diseases. 6/15/2024, Vol. 78 Issue 6, p1451-1457. 7p.
Publication Year :
2024

Abstract

Background The high mortality of systemic anthrax is likely a consequence of the severe central nervous system inflammation that occurs in anthrax meningitis. Effective treatment of such infections requires, at a minimum, adequate cerebrospinal fluid (CSF) antimicrobial concentrations. Methods We reviewed English medical literature and regulatory documents to extract information on serum and CSF exposures for antimicrobials with in vitro activity against Bacillus anthracis. Using CSF pharmacokinetic exposures and in vitro B. anthracis susceptibility data, we used population pharmacokinetic modeling and Monte Carlo simulations to determine whether a specific antimicrobial dosage would likely achieve effective CSF antimicrobial activity in patients with normal to inflamed meninges (ie, an intact to markedly disrupted blood–brain barrier). Results The probability of microbiologic success at achievable antimicrobial dosages was high (≥95%) for ciprofloxacin, levofloxacin (500 mg every 12 hours), meropenem, imipenem/cilastatin, penicillin G, ampicillin, ampicillin/sulbactam, doxycycline, and minocycline; acceptable (90%–95%) for piperacillin/tazobactam and levofloxacin (750 mg every 24 hours); and low (<90%) for vancomycin, amikacin, clindamycin, and linezolid. Conclusions Prompt empiric antimicrobial therapy of patients with suspected or confirmed anthrax meningitis may reduce the high morbidity and mortality. Our data support using several β-lactam-, fluoroquinolone-, and tetracycline-class antimicrobials as first-line and alternative agents for treatment of patients with anthrax meningitis; all should achieve effective microbiologic exposures. Our data suggest antimicrobials that should not be relied on to treat suspected or documented anthrax meningitis. Furthermore, the protein synthesis inhibitors clindamycin and linezolid can decrease toxin production and may be useful components of combination therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10584838
Volume :
78
Issue :
6
Database :
Academic Search Index
Journal :
Clinical Infectious Diseases
Publication Type :
Academic Journal
Accession number :
177927010
Full Text :
https://doi.org/10.1093/cid/ciae093